Regeneron to Report Second Quarter 2018 Financial and Operating Results and Host Conference Call and Webcast on August 2, 2018
- Wall Street ends sharply higher, led by surging Dow
- Sanderson Farms (SAFM) Explores Sale - Report
- Amazon (AMZN) in Talks to Acquire Stake in Self-Driving Truck Startup Plus: Report
- Dollar dips after Fed rally, Bitcoin slumps
- 5 Companies Set to Hike Their Dividend Over the Next Few Weeks, 3 Dividend Aristocrats
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
TARRYTOWN, N.Y., July 9, 2018 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its second quarter 2018 financial and operating results on Thursday, August 2, 2018, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day.
Conference Call InformationTo access this call, dial (800) 708-4539 (U.S.) or (847) 619-6396 (International). A link to the webcast may be accessed from the 'Investors and Media' page of Regeneron's website at www.regeneron.com. A replay of the conference call and webcast will be archived on the Company's website and will be available for 30 days.
About Regeneron Pharmaceuticals, Inc.Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to six FDA-approved treatments and numerous product candidates in development, all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye disease, heart disease, allergic and inflammatory diseases, pain, cancer, infectious diseases and rare diseases.
Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite® technologies, such as VelocImmune® which produces optimized fully-human antibodies, and ambitious research initiatives such as the Regeneron Genetics Center, which is conducting one of the largest genetics sequencing efforts in the world.
For additional information about the company, please visit www.regeneron.com or follow @Regeneron on Twitter.
Manisha Narasimhan, Ph.D.
View original content:http://www.prnewswire.com/news-releases/regeneron-to-report-second-quarter-2018-financial-and-operating-results-and-host-conference-call-and-webcast-on-august-2-2018-300676748.html
SOURCE Regeneron Pharmaceuticals, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Defence Therapeutics AccuTOX Exhibits Potent Anti-Cancer Properties
- IoT partners Pycom and 1NCE cut costs of full-stack IoT with an all-in offering starting at 1 Euro
- Lynx Pan-Global Payment Network Processes US$78 Million in Its First Full 60 Days of Operation
Create E-mail Alert Related CategoriesPress Releases
Related EntitiesTwitter, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!